Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) EBIT (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of EBIT data on record, last reported at -$22.7 million in Q4 2025.

  • For Q4 2025, EBIT rose 77.19% year-over-year to -$22.7 million; the TTM value through Dec 2025 reached -$76.4 million, up 46.19%, while the annual FY2025 figure was -$76.4 million, 46.19% up from the prior year.
  • EBIT reached -$22.7 million in Q4 2025 per ACRS's latest filing, down from -$17.1 million in the prior quarter.
  • Across five years, EBIT topped out at -$4.0 million in Q4 2023 and bottomed at -$99.7 million in Q4 2024.
  • Average EBIT over 5 years is -$24.8 million, with a median of -$20.6 million recorded in 2021.
  • Peak YoY movement for EBIT: soared 86.08% in 2023, then crashed 2362.94% in 2024.
  • A 5-year view of EBIT shows it stood at -$22.9 million in 2021, then fell by 27.02% to -$29.1 million in 2022, then skyrocketed by 86.08% to -$4.0 million in 2023, then plummeted by 2362.94% to -$99.7 million in 2024, then soared by 77.19% to -$22.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were -$22.7 million in Q4 2025, -$17.1 million in Q3 2025, and -$18.4 million in Q2 2025.